[go: up one dir, main page]

ES2804624T3 - Methods of treating psoriatic arthritis using il-17 antagonists - Google Patents

Methods of treating psoriatic arthritis using il-17 antagonists

Info

Publication number
ES2804624T3
ES2804624T3 ES20187001T ES20187001T ES2804624T3 ES 2804624 T3 ES2804624 T3 ES 2804624T3 ES 20187001 T ES20187001 T ES 20187001T ES 20187001 T ES20187001 T ES 20187001T ES 2804624 T3 ES2804624 T3 ES 2804624T3
Authority
ES
Spain
Prior art keywords
antagonists
methods
psoriatic arthritis
treating psoriatic
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20187001T
Other languages
English (en)
Other versions
ES2804624T1 (es
Inventor
Shepard Mpofu
Hanno Richards
Karthinathan Thangavelu
Matthias Machacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2804624(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of ES2804624T1 publication Critical patent/ES2804624T1/es
Application granted granted Critical
Publication of ES2804624T3 publication Critical patent/ES2804624T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un anticuerpo antagonista de IL-17 para su uso en el tratamiento de la artritis inflamatoria, caracterizado por que el anticuerpo antagonista de IL-17 se va a administrar por via subcutanea, donde la artritis inflamatoria es espondiloartropatia, espondilitis anquilosante o artritis psoriasica.
ES20187001T 2010-11-05 2011-11-04 Methods of treating psoriatic arthritis using il-17 antagonists Active ES2804624T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05

Publications (2)

Publication Number Publication Date
ES2804624T1 ES2804624T1 (es) 2021-02-08
ES2804624T3 true ES2804624T3 (en) 2026-01-23

Family

ID=44906168

Family Applications (3)

Application Number Title Priority Date Filing Date
ES16163440T Active ES2733712T3 (es) 2010-11-05 2011-11-04 Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
ES20187001T Active ES2804624T3 (en) 2010-11-05 2011-11-04 Methods of treating psoriatic arthritis using il-17 antagonists
ES21180656T Active ES3030036T3 (en) 2010-11-05 2011-11-04 Pharmaceutical compositions comprising secukinumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES16163440T Active ES2733712T3 (es) 2010-11-05 2011-11-04 Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES21180656T Active ES3030036T3 (en) 2010-11-05 2011-11-04 Pharmaceutical compositions comprising secukinumab

Country Status (31)

Country Link
US (10) US9744234B2 (es)
EP (6) EP3542820A1 (es)
JP (8) JP2014503482A (es)
KR (5) KR20180019247A (es)
CN (2) CN104800844A (es)
AU (1) AU2011325134B2 (es)
BR (1) BR112013011176A2 (es)
CA (2) CA2813849C (es)
CL (1) CL2013001213A1 (es)
CY (1) CY1121802T1 (es)
DE (1) DE20187001T1 (es)
DK (2) DK3111954T3 (es)
ES (3) ES2733712T3 (es)
FI (1) FI3757126T3 (es)
HR (2) HRP20251174T1 (es)
HU (1) HUE044038T2 (es)
IL (4) IL311014A (es)
LT (2) LT3111954T (es)
MA (1) MA34647B1 (es)
MX (1) MX362591B (es)
PH (1) PH12013500890A1 (es)
PL (1) PL3111954T3 (es)
PT (2) PT3757126T (es)
RS (1) RS67377B1 (es)
RU (1) RU2582937C2 (es)
SG (2) SG10201505624VA (es)
SI (2) SI3111954T1 (es)
SM (1) SMT202500423T1 (es)
TR (1) TR201909531T4 (es)
TW (3) TWI604851B (es)
WO (1) WO2012059598A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Ｈｅｒ３와 관련된 생물학적 물질들
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
HRP20201513T1 (hr) 2011-10-11 2020-12-11 Viela Bio, Inc. Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9688769B2 (en) 2013-10-22 2017-06-27 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
JP2017508446A (ja) * 2014-01-28 2017-03-30 北京韓美薬品有限公司 二機能性融合タンパク質及びその製造方法並びに使用
CN106456756B (zh) 2014-05-13 2021-04-23 免疫医疗有限公司 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
US20160002326A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2017003216A (es) * 2014-09-10 2017-05-23 Novartis Ag Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
ES2941234T3 (es) * 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
IL297775A (en) * 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US20190183991A1 (en) * 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
US20210179702A1 (en) * 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EP3790576A1 (en) * 2018-05-09 2021-03-17 Novartis Ag Use of canakinumab
US20210340200A1 (en) * 2018-09-26 2021-11-04 Viela Bio, Inc. Cd40l antagonist and uses thereof
CA3125236A1 (en) * 2019-01-22 2020-07-30 F. Hoffmann-La Roche Ag Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP4010077A1 (en) * 2019-08-05 2022-06-15 Evelo Biosciences, Inc. Compositions and methods of treating psoriasis and atopic dermatitis using prevotella histicola
TW202539734A (zh) * 2019-09-20 2025-10-16 瑞士商諾華公司 使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法
JP2023502103A (ja) 2019-11-19 2023-01-20 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2022113105A1 (en) * 2020-11-25 2022-06-02 Dr. Reddy's Laboratories Limited Stable therapeutic protein formulation and methods of making the same
TW202241505A (zh) * 2021-01-04 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
KR20240024929A (ko) * 2021-06-21 2024-02-26 브리스톨-마이어스 스큅 컴퍼니 고농도 동결건조 생물제제 약물 제품의 재구성 시간을 감소시키기 위한 수크로스, 만니톨 및 글리신의 용도
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
WO2025071335A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-17 항체의 안정한 액상 제형

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) * 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
PT1133558E (pt) 1998-11-27 2007-01-31 Ucb Sa Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MXPA04004459A (es) 2001-11-09 2005-05-16 Johnson & Johnson Composiciones liofilizadas de anticuerpo monoclonal.
JP4662714B2 (ja) 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007056188A1 (en) 2005-11-04 2007-05-18 President And Fellows Of Harvard College Synthesis of inhibitors of ftsz
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
US8012477B2 (en) * 2006-01-31 2011-09-06 Novartis Ag Methods of treating multiple myeloma using IL-17 binding molecules
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
MX2009008096A (es) 2007-02-02 2009-08-07 Novartis Ag Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
JP2010524846A (ja) 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
EA200970880A1 (ru) 2007-03-22 2010-02-26 Имклоун Элэлси Стабильные композиции на основе антител
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
EP2171449A2 (en) 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101896201A (zh) 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
TW201012475A (en) 2008-07-08 2010-04-01 Abbott Lab Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
RU2011140335A (ru) 2009-03-05 2013-04-10 Эбботт Лэборетриз Связывающие il-17 белки
HRP20180301T1 (hr) 2010-10-08 2018-03-23 Novartis Ag Postupci liječenja psorijaze uporabom il-17 antagonista
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
KR20140097178A (ko) 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
CA2870025A1 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
JP6515168B2 (ja) 2019-05-15
US20200276305A1 (en) 2020-09-03
CA2813849A1 (en) 2012-05-10
JP2016065094A (ja) 2016-04-28
RU2013125775A (ru) 2014-12-10
CY1121802T1 (el) 2020-07-31
TR201909531T4 (tr) 2019-07-22
PT3757126T (pt) 2025-11-13
JP2018065826A (ja) 2018-04-26
US20130209480A1 (en) 2013-08-15
MA34647B1 (fr) 2013-11-02
TWI618543B (zh) 2018-03-21
TWI616204B (zh) 2018-03-01
CA2813849C (en) 2021-06-15
PT3111954T (pt) 2019-07-10
HRP20191162T1 (hr) 2019-10-04
JP2017002064A (ja) 2017-01-05
US20230346926A1 (en) 2023-11-02
US20250205332A1 (en) 2025-06-26
ES2733712T3 (es) 2019-12-02
AU2011325134B2 (en) 2014-10-23
EP3757126B1 (en) 2025-09-03
IL311014A (en) 2024-04-01
US11534491B2 (en) 2022-12-27
US20230293683A1 (en) 2023-09-21
CA3116725C (en) 2023-10-24
TW201517917A (zh) 2015-05-16
JP6049843B2 (ja) 2016-12-21
JP2025102772A (ja) 2025-07-08
HUE044038T2 (hu) 2019-09-30
WO2012059598A3 (en) 2012-09-27
MX2013005060A (es) 2013-06-28
US12465635B2 (en) 2025-11-11
US20180008706A1 (en) 2018-01-11
DE20187001T1 (de) 2021-04-01
KR20160067984A (ko) 2016-06-14
SG189138A1 (en) 2013-05-31
RU2582937C2 (ru) 2016-04-27
CN103189074A (zh) 2013-07-03
EP3542820A1 (en) 2019-09-25
EP3912640A1 (en) 2021-11-24
EP3912640B1 (en) 2025-03-05
WO2012059598A2 (en) 2012-05-10
US20190307880A1 (en) 2019-10-10
AU2011325134A1 (en) 2013-04-04
KR20140008305A (ko) 2014-01-21
EP3111954B1 (en) 2019-04-03
CN104800844A (zh) 2015-07-29
EP3111954A1 (en) 2017-01-04
JP2014503482A (ja) 2014-02-13
IL262559B (en) 2022-06-01
PL3111954T3 (pl) 2019-10-31
SMT202500423T1 (it) 2026-01-12
IL225309B (en) 2021-05-31
EP2635303A2 (en) 2013-09-11
LT3111954T (lt) 2019-07-10
KR20180129991A (ko) 2018-12-05
EP3757126A1 (en) 2020-12-30
SG10201505624VA (en) 2015-09-29
JP2023109910A (ja) 2023-08-08
DK3111954T3 (da) 2019-07-15
LT3757126T (lt) 2025-12-10
US20220193234A1 (en) 2022-06-23
JP2019142912A (ja) 2019-08-29
US9744234B2 (en) 2017-08-29
EP4116325A1 (en) 2023-01-11
RS67377B1 (sr) 2025-11-28
KR20150020734A (ko) 2015-02-26
KR20180019247A (ko) 2018-02-23
IL262559A (en) 2018-12-31
SI3111954T1 (sl) 2019-08-30
BR112013011176A2 (pt) 2020-09-01
US10363307B2 (en) 2019-07-30
IL225309A0 (en) 2013-06-27
ES3030036T3 (en) 2025-06-26
SI3757126T1 (sl) 2025-12-31
TW201726170A (zh) 2017-08-01
TWI604851B (zh) 2017-11-11
JP6250109B2 (ja) 2017-12-20
MX362591B (es) 2019-01-25
US20210128726A1 (en) 2021-05-06
CL2013001213A1 (es) 2014-03-28
HRP20251174T1 (hr) 2025-11-21
IL282625A (en) 2021-06-30
US20210177966A1 (en) 2021-06-17
CA3116725A1 (en) 2012-05-10
JP2021104995A (ja) 2021-07-26
PH12013500890A1 (en) 2013-07-01
FI3757126T3 (fi) 2025-10-12
DK3757126T3 (da) 2025-09-29
TW201306864A (zh) 2013-02-16
ES2804624T1 (es) 2021-02-08

Similar Documents

Publication Publication Date Title
ES2804624T3 (en) Methods of treating psoriatic arthritis using il-17 antagonists
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
EA201591293A1 (ru) Способы и композиции для доставки антител, кодируемых мрнк
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CY1125490T1 (el) Συνθεση για χρηση σε μια μεθοδο θεραπειας υπερβολικου βαρους και παχυσαρκιας σε ασθενεις με υψηλο καρδιαγγειακο κινδυνο
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
MX2014014946A (es) Uso de peptidos glp-1 de accion prolongada.
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX2015007034A (es) Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
NZ604510A (en) Dilutable biocidal compositions and methods of use
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
CL2008001674A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-fator de crecimiento endotlial vascular (vegf); acido nucleoico que lo codifica; vector y celula huesped; metodo de produccion; antagonosta de vegf que comprende el dab; composiicon que comprende al antagonista; y uso del antagonista para prepara un medicamento.
BR112015003282A2 (pt) composições de cimento de geopolímero e métodos de uso
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23